Literature DB >> 16755173

Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer.

Prajnan Das1, John M Skibber, Miguel A Rodriguez-Bigas, Barry W Feig, George J Chang, Paulo M Hoff, Cathy Eng, Robert A Wolff, Nora A Janjan, Marc E Delclos, Sunil Krishnan, Lawrence B Levy, Lee M Ellis, Christopher H Crane.   

Abstract

OBJECTIVES: To identify predictive factors for locoregional recurrence (LR), distant metastasis (DM), and overall survival (OS) in patients treated with chemoradiation and surgery for rectal cancer.
METHODS: Between 1989 and 2001, 470 patients with rectal cancer were treated with preoperative (89%) or postoperative (11%) chemoradiation and mesorectal excision. Median radiation dose was 45 Gy; 97% received concurrent infusional 5-fluorouracil, and 65% received adjuvant chemotherapy. Median follow-up interval was 5.7 years.
RESULTS: The 5-year rates of freedom from LR, freedom from DM, and OS were 90%, 79%, and 80%, respectively. On univariate analysis, significant predictors of LR were female sex, clinical T stage, pathologic T and N stages, and positive radial margin. Significant univariate predictors of DM were circumferential extent of tumor, tumor immobility, lymphovascular invasion, perineural involvement, and pathologic T and N stages. Significant univariate predictors of lower OS were age, circumferential extent of tumor, shorter distance from anal verge, tumor size, tumor immobility, anal canal involvement, lymphovascular invasion, perineural involvement, positive radial margin, and pathologic T and N stages. On Cox multivariate analysis, female sex and pathologic T and N stages independently predicted for LR; pathologic T and N stages independently predicted for DM; and age, circumferential extent of tumor, positive radial margin, and pathologic T and N stages independently predicted for lower OS.
CONCLUSIONS: Pathologic T and N stages significantly predicted for all 3 end points (LR, DM and OS) on multivariate analysis. Investigations of more aggressive adjuvant chemotherapy appear warranted for pathologic stage T3/T4 or N1/2 rectal cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16755173     DOI: 10.1097/01.coc.0000214930.78200.4a

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  55 in total

1.  A case for more intensive systemic therapy for patients with locally advanced rectal cancer: even in the face of a pathologic complete response.

Authors:  Max Vergo; Al B Benson
Journal:  Gastrointest Cancer Res       Date:  2011-05

2.  Adjuvant radiotherapy following total mesorectal excision for stage IIA rectal cancer: is it beneficial?

Authors:  Jin Soo Kim; Nam Kyu Kim; Byung Soh Min; Hyuk Hur; Joong Bae Ahn; Ki Chang Keum
Journal:  Int J Colorectal Dis       Date:  2010-06-11       Impact factor: 2.571

Review 3.  Adjuvant chemotherapy for rectal cancer: Is it needed?

Authors:  Kristijonas Milinis; Michael Thornton; Amir Montazeri; Paul S Rooney
Journal:  World J Clin Oncol       Date:  2015-12-10

4.  Clinical implication of additional selective lateral lymph node excision in patients with locally advanced rectal cancer who underwent preoperative chemoradiotherapy.

Authors:  Seok-Byung Lim; Chang Sik Yu; Chan Wook Kim; Yong Sik Yoon; Seong Ho Park; Tae Won Kim; Jong Hoon Kim; Jin Cheon Kim
Journal:  Int J Colorectal Dis       Date:  2013-08-14       Impact factor: 2.571

5.  Pretreatment high-resolution rectal MRI and treatment response to neoadjuvant chemoradiation.

Authors:  George J Chang; Y Nancy You; In Ja Park; Harmeet Kaur; Chung-Yuan Hu; Miguel A Rodriguez-Bigas; John M Skibber; Randy D Ernst
Journal:  Dis Colon Rectum       Date:  2012-04       Impact factor: 4.585

6.  The impact of surgical diversion before neoadjuvant therapy for rectal cancer.

Authors:  Brandon J Anderson; Elizabeth G Hill; Robert E Sweeney; Amy E Wahlquist; David T Marshall; Kevin F Staveley O'Carroll; David J Cole; Ernest Ramsay Camp
Journal:  Am Surg       Date:  2015-05       Impact factor: 0.688

7.  Selecting patients for hyperthermia combined with preoperative chemoradiotherapy for locally advanced rectal cancer.

Authors:  Sang-Won Kim; Ji Woon Yea; Jae Hwang Kim; Mi Jin Gu; Min Kyu Kang
Journal:  Int J Clin Oncol       Date:  2017-11-13       Impact factor: 3.402

Review 8.  Current issues in locally advanced colorectal cancer treated by preoperative chemoradiotherapy.

Authors:  In Ja Park; Chang Sik Yu
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

Review 9.  Pathological complete response after neoadjuvant therapy for rectal cancer and the role of adjuvant therapy.

Authors:  Valerie M Nelson; Al B Benson
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

10.  Allelotyping identification of genomic alterations in rectal chromosomally unstable tumors without preoperative treatment.

Authors:  Benoît Romain; Agnès Neuville; Nicolas Meyer; Cécile Brigand; Serge Rohr; Anne Schneider; Marie-Pierre Gaub; Dominique Guenot
Journal:  BMC Cancer       Date:  2010-10-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.